Francesco Serra

Dr. Francesco Serra

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2022 in Drugs in Context
Verified
Journal Article
Open access
FSFrancesco Serra
Francesco Serra
PPPaolo Pedrazzoli
Paolo Pedrazzoli
SBSilvia Brugnatelli
Silvia Brugnatelli
APAnna Pagani
Anna Pagani
SCSalvatore Corallo
Salvatore Corallo
OCOrnella Carminati
Ornella Carminati
This narrative review presents the most recent data on nutritional support in the resectable stages of gastric cancer, with a particular focus on perioperative strategies, and discusses malnutrition in gastric cancer, nutritional support before and after surgery, and the relationship between nutritional support and chemotherapy.

3 January 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
ACAmanda Casirati
Amanda Casirati
VPValentina Da Prat
Valentina Da Prat
ECEmanuele Cereda
Emanuele Cereda
FSFrancesco Serra
Francesco Serra
LPLorenzo Perrone
Lorenzo Perrone
Riccardo CaccialanzaRiccardo Caccialanza
Riccardo Caccialanza
Malnutrition is a common condition in cancer patients

9 August 2021 in Drugs in Context
Verified
Journal Article
Open access
FSFrancesco Serra
Francesco Serra
CFCarlotta Faverio
Carlotta Faverio
ALAngioletta Lasagna
Angioletta Lasagna
SBStefania Barruscotti
Stefania Barruscotti
TDTommaso Dominioni
Tommaso Dominioni
SCSilvia Chiellino
Silvia Chiellino
The clinical management of BRAF-mutated metastatic melanoma had an important turning point after the introduction of the targeted therapy. Despite the efficacy and good tolerability of this treatment, the development of resistance mechanisms causes disease progression. The aim of this review is to investigate the role of treatment beyond progression and locoregional approaches in BRAF-mutated metastatic melanoma and provide oncologists dealing with this malignancy a useful road map on when and why to choose this strategy.

Verified
Journal Article
Open access
PDF file
Roberto AquilaniRoberto Aquilani
Roberto Aquilani
SBSilvia Brugnatelli
Silvia Brugnatelli
RMRoberto Maestri
Roberto Maestri
Paolo IadarolaPaolo Iadarola
Paolo Iadarola
SCSalvatore Corallo
Salvatore Corallo
MVManuela Verri
Manuela Verri
Previous studies have documented that FOLFOX and XELOX therapies negatively impact the metabolism of skeletal muscle and extra-muscle districts. This pilot study tested whether three-month FOLFOX or XELOX therapy produced changes in plasma amino acid levels (PAAL) (an estimation of whole-body amino acid metabolism) and in plasma levels of malondialdehyde (MDA), a marker of lipid hyper oxidation. Fourteen ambulatory, resected patients with colorectal cancer scheduled to receive FOLFOX (n = 9) or XELOX (n = 5) therapy, after overnight fasting, underwent peripheral venous blood sampling, to determine PAAL and MDA before, during, and at the end of three-month therapy. Fifteen healthy matched subjects (controls) only underwent measures of PAAL at baseline. The results showed changes in 87.5% of plasma essential amino acids (EAAs) and 38.4% of non-EAAs in patients treated with FOLFOX or XELOX. These changes in EAAs occurred in two opposite directions: EAAs decreased with FOLFOX and increased or did not decrease with XELOX (interactions: from p = 0.034 to p = 0.003). Baseline plasma MDA levels in both FOLFOX and XELOX patients were above the normal range of values, and increased, albeit not significantly, during therapy. In conclusion, three-month FOLFOX or XELOX therapy affected plasma EAAs differently but not the baseline MDA levels, which were already high.

29 October 2025
Verified
Journal Article
Open access
FRFrancesca Rifaldi
Francesca Rifaldi
DADomiziana Alaimo
Domiziana Alaimo
ATAnna Tortorella
Anna Tortorella
IIIlaria Imarisio
Ilaria Imarisio
APAnna Pagani
Anna Pagani
FSFrancesco Serra
Francesco Serra
The authors present a case of pineal metastasis from oesophageal adenocarcinoma managed by multimodal treatment and compare their observations with the available literature on this disease entity.

18 February 2025 in Drugs in Context
Verified
Journal Article
Open access
FSFrancesco Serra
Francesco Serra
FVFederica Valerio
Federica Valerio
PPPaolo Pedrazzoli
Paolo Pedrazzoli
JVJacopo Viganò
Jacopo Viganò
Riccardo CaccialanzaRiccardo Caccialanza
Riccardo Caccialanza
SCSalvatore Corallo
Salvatore Corallo
This article aims to demonstrate the real-life effectiveness of the fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) regimen by comparing it with traditional chemotherapy regimens and aims to discover its strengths and weaknesses.